Workflow
赛升药业(300485) - 2022 Q3 - 季度财报

Financial Performance - Revenue for Q3 2022 was CNY 215,891,125.90, a decrease of 24.92% compared to the same period last year[3] - Net profit attributable to shareholders was CNY 18,443,537.92, down 64.79% year-on-year[3] - Basic earnings per share decreased by 63.64% to CNY 0.04[3] - The net profit for the third quarter of 2022 reached CNY 250,180,916.41, an increase of 88.17% compared to CNY 132,956,669.56 in the same period last year[10] - The total profit amounted to CNY 283,045,644.26, reflecting a growth of 79.19% from CNY 157,957,424.57 year-on-year[10] - The operating profit increased by 79.19% to CNY 283,067,954.35, driven by higher investment income from joint ventures and changes in the fair value of financial assets[10] - The company's basic earnings per share rose to CNY 0.52, marking a 79.31% increase from CNY 0.29 in the previous year[11] - Total operating revenue for the current period was ¥599,234,034.97, a decrease of 26.0% compared to ¥809,479,013.21 in the previous period[23] - Net profit for the current period was ¥250,180,916.41, an increase of 88.5% compared to ¥132,956,669.56 in the previous period[24] - The company reported a basic and diluted earnings per share of ¥0.52, up from ¥0.29 in the previous period[25] Assets and Equity - Total assets increased by 4.97% to CNY 3,570,725,389.62 compared to the end of the previous year[4] - Owner's equity attributable to shareholders rose by 5.40% to CNY 3,420,096,193.97[4] - Total assets rose to ¥3,570,725,389.62, compared to ¥3,401,649,422.52 in the previous period, reflecting a growth of 5.0%[21] - The company's total equity increased to ¥3,456,594,955.95 from ¥3,283,105,830.65 in the previous period[21] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 90,144,873.36, down 28.47%[3] - Cash and cash equivalents at the end of the period decreased by 69.72% to CNY 119,581,121.81, attributed to a reduction in cash reserves[12] - The company's cash and cash equivalents decreased from CNY 161,543,438.37 at the beginning of the year to CNY 119,581,121.81 by September 30, 2022, a decline of approximately 26%[19] - The net cash flow from operating activities for the current period is ¥90,144,873.36, a decrease of 28.5% compared to ¥126,025,973.11 in the previous period[26] - Cash and cash equivalents at the end of the period amount to ¥119,581,121.81, down from ¥394,967,167.05 in the previous period[27] Investment and Expenses - Investment income increased by 208.29% to CNY 90,531,418.02, mainly due to higher equity method investment income[9] - Sales expenses decreased by 31.18% to CNY 294,296,573.46, attributed to reduced marketing activities[9] - Research and development expenses were ¥79,555,905.38, slightly down from ¥80,473,801.38 in the previous period[23] - The company achieved an investment income of ¥90,531,418.02, significantly up from ¥29,365,431.82 in the previous period[24] Inventory and Liabilities - Inventory decreased by 30.61% to CNY 85,392,157.97, primarily due to reduced raw material purchases[9] - The total current assets decreased from CNY 1,530,193,553.81 to CNY 1,464,545,372.82, a reduction of about 4.3%[19] - Total liabilities decreased to ¥114,130,433.67 from ¥118,543,591.87 in the previous period[21] Strategic Developments - The company established a venture capital fund with an investment of CNY 10 million, and acquired an 18% stake in Beijing Haijing Biomedical Technology Co., Ltd. for CNY 7.2 million[15] - The company signed a strategic cooperation framework agreement with Beijing Tianguangshi Biotechnology Co., Ltd. to enhance collaboration in drug development and production[16] - The subsidiary Junyuan Pharmaceutical obtained a drug production license from the Liaoning Provincial Drug Administration[16] - The company is currently conducting Phase I clinical trials for a humanized anti-VEGF monoclonal antibody injection, which is a key product under development[17] Other Financial Metrics - Non-recurring gains and losses totaled CNY 7,781,671.26 for the current period[6] - The income tax expense rose by 31.45% to CNY 32,864,727.85, driven by the increase in profits[10] - The total comprehensive income for the period was CNY 253,797,441.83, an increase of 91.17% compared to CNY 132,759,296.71 in the previous year[11] - The cash paid for purchasing goods and services decreased by 32.32% to CNY 84,357,054.43, reflecting a reduction in raw material procurement[11] - The company experienced a foreign exchange impact on cash and cash equivalents of ¥2,457,965.42, compared to -¥134,172.85 in the previous period[27] Shareholder Information - The total number of common shareholders at the end of the reporting period is 34,687[13] - The largest shareholder, Ma Jiao, holds 49.51% of the shares, totaling 238,464,000 shares[13] Audit Status - The company has not undergone an audit for the third quarter report[28]